366 related articles for article (PubMed ID: 20233996)
21. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
22. Three-gene prognostic classifier for early-stage non small-cell lung cancer.
Lau SK; Boutros PC; Pintilie M; Blackhall FH; Zhu CQ; Strumpf D; Johnston MR; Darling G; Keshavjee S; Waddell TK; Liu N; Lau D; Penn LZ; Shepherd FA; Jurisica I; Der SD; Tsao MS
J Clin Oncol; 2007 Dec; 25(35):5562-9. PubMed ID: 18065728
[TBL] [Abstract][Full Text] [Related]
23. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
25. Prognostic evaluation of nodal staging based on the new IASLC lymph node map for lung cancer.
Takamochi K; Oh S; Suzuki K
Thorac Cardiovasc Surg; 2010 Sep; 58(6):345-9. PubMed ID: 20824587
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
27. The coming of age of molecular tumor profiling.
Antonoff MB; D'Cunha J
Semin Thorac Cardiovasc Surg; 2011; 23(1):8-9. PubMed ID: 21807290
[TBL] [Abstract][Full Text] [Related]
28. Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers.
Bunn PA; Kim ES
Clin Lung Cancer; 2015 Jul; 16(4):245-51. PubMed ID: 25887065
[TBL] [Abstract][Full Text] [Related]
29. Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer.
Qi L; Chen L; Li Y; Qin Y; Pan R; Zhao W; Gu Y; Wang H; Wang R; Chen X; Guo Z
Brief Bioinform; 2016 Mar; 17(2):233-42. PubMed ID: 26254430
[TBL] [Abstract][Full Text] [Related]
30. Integrative analysis of lung development-cancer expression associations reveals the roles of signatures with inverse expression patterns.
Zhang C; Li C; Xu Y; Feng L; Shang D; Yang X; Han J; Sun Z; Li Y; Li X
Mol Biosyst; 2015 May; 11(5):1271-84. PubMed ID: 25720795
[TBL] [Abstract][Full Text] [Related]
31. Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice.
Michiels S; Ternès N; Rotolo F
Ann Oncol; 2016 Dec; 27(12):2160-2167. PubMed ID: 27634691
[TBL] [Abstract][Full Text] [Related]
32. Review and cross-validation of gene expression signatures and melanoma prognosis.
Schramm SJ; Campain AE; Scolyer RA; Yang YH; Mann GJ
J Invest Dermatol; 2012 Feb; 132(2):274-83. PubMed ID: 21956122
[TBL] [Abstract][Full Text] [Related]
33. Prognostic gene signatures for non-small-cell lung cancer.
Boutros PC; Lau SK; Pintilie M; Liu N; Shepherd FA; Der SD; Tsao MS; Penn LZ; Jurisica I
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2824-8. PubMed ID: 19196983
[TBL] [Abstract][Full Text] [Related]
34. Lung cancer staging in the genomics era.
Nguyen DM; Schrump DS
Thorac Surg Clin; 2006 Nov; 16(4):329-37. PubMed ID: 17240820
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
Schwartz AM; Henson DE;
Chest; 2007 Sep; 132(3 Suppl):78S-93S. PubMed ID: 17873162
[TBL] [Abstract][Full Text] [Related]
36. What should physicians look for in evaluating prognostic gene-expression signatures?
Subramanian J; Simon R
Nat Rev Clin Oncol; 2010 Jun; 7(6):327-34. PubMed ID: 20421890
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature.
Tschodu D; Ulm B; Bendrat K; Lippoldt J; Gottheil P; Käs JA; Niendorf A
PLoS One; 2022; 17(2):e0261035. PubMed ID: 35143511
[TBL] [Abstract][Full Text] [Related]
38. A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures.
Starmans MH; Fung G; Steck H; Wouters BG; Lambin P
PLoS One; 2011; 6(12):e28320. PubMed ID: 22163293
[TBL] [Abstract][Full Text] [Related]
39. Gene-expression signatures in oncology diagnostics.
Mazumder A; Wang Y
Pharmacogenomics; 2006 Dec; 7(8):1167-73. PubMed ID: 17184204
[TBL] [Abstract][Full Text] [Related]
40. Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic data.
Fortney K; Griesman J; Kotlyar M; Pastrello C; Angeli M; Sound-Tsao M; Jurisica I
PLoS Comput Biol; 2015 Mar; 11(3):e1004068. PubMed ID: 25786242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
